Skip to main content

ICH Q10 Pharmaceutical quality system (EMA/CHMP/ICH/214732/2007)

 ICH Q10, titled "Pharmaceutical Quality System" (EMA/CHMP/ICH/214732/2007), is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline provides recommendations on establishing a pharmaceutical quality system (PQS) within the pharmaceutical industry to ensure the consistent production of high-quality pharmaceutical products. Here's an elaboration of ICH Q10:


1. Purpose of ICH Q10:

The primary purpose of ICH Q10 is to provide a harmonized framework for the implementation of a quality management system in pharmaceutical manufacturing. It emphasizes the importance of a proactive and integrated approach to quality assurance and regulatory compliance.

2. Scope:

ICH Q10 applies to the pharmaceutical quality system used throughout the product lifecycle, from product development and technology transfer to manufacturing, distribution, and post-marketing activities.

3. Core Principles:

ICH Q10 outlines a set of core principles that should guide the development and operation of the pharmaceutical quality system. These principles include a focus on patient safety, product quality, risk management, and a lifecycle approach to quality.

4. Quality Management System (QMS):

The guideline emphasizes the establishment and maintenance of a robust quality management system (QMS) that covers all aspects of pharmaceutical operations. The QMS should include policies, procedures, processes, and responsibilities related to quality.

5. Pharmaceutical Quality System Elements:

ICH Q10 defines several key elements of the pharmaceutical quality system, including quality risk management, a product quality review (PQR) system, process performance and product quality monitoring, and management of outsourced activities.

6. Risk Management:

The guideline encourages the systematic application of quality risk management (QRM) principles throughout the product lifecycle. Risk assessments should be conducted to identify, evaluate, and control risks to product quality and patient safety.

7. Change Management:

ICH Q10 emphasizes the importance of change management within the pharmaceutical quality system. Changes to processes, procedures, and specifications should be assessed for their impact on product quality and regulatory compliance.

8. Continual Improvement:

A culture of continual improvement is promoted in ICH Q10. Pharmaceutical companies are encouraged to monitor and analyze data, learn from deviations and non-conformities, and take corrective and preventive actions to enhance their quality systems.

9. Regulatory Expectations:

Regulatory authorities expect pharmaceutical companies to have a well-defined pharmaceutical quality system in place. Compliance with ICH Q10 is typically required during regulatory inspections and is a key aspect of demonstrating good manufacturing practices (GMP).

10. Documentation:

- Comprehensive documentation is essential within the pharmaceutical quality system. Manufacturers should maintain records of quality-related activities, including risk assessments, change control, and PQRs.

11. Training and Competency:

- Personnel involved in the pharmaceutical quality system should receive appropriate training and possess the necessary competence to carry out their roles effectively.

12. Lifecycle Approach:

- ICH Q10 promotes a lifecycle approach to product quality. Manufacturers should consider quality aspects from product development through commercialization and post-marketing, ensuring ongoing product quality.


In summary, ICH Q10 provides a structured framework for the establishment and maintenance of a pharmaceutical quality system that ensures the consistent production of high-quality pharmaceutical products. Compliance with this guideline helps pharmaceutical companies proactively manage risks, maintain regulatory compliance, and continuously improve their quality systems to benefit patients and consumers

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

ICH E3 Structure and content of clinical study reports (CPMP/ICH/137/95)

 The ICH E3 guideline, titled "Structure and Content of Clinical Study Reports," with the reference number CPMP/ICH/137/95, provides recommendations and a standardized framework for the structure and content of clinical study reports (CSRs). CSRs are essential documents that summarize the results and findings of clinical trials conducted during the drug development process. Here's an elaboration of ICH E3: 1. Purpose: The primary purpose of ICH E3 is to provide guidance on the organization, content, and format of CSRs to ensure consistency and clarity in reporting clinical trial data. It aims to facilitate the evaluation of the safety and efficacy of investigational drugs by regulatory authorities. 2. Applicability: ICH E3 is applicable to CSRs for all phases of clinical trials, including Phase I, II, III, and post-marketing studies. 3. Structure of the CSR: The guideline outlines a standardized structure for the CSR, which typically includes the following sections: Title...
Read more

ICH 5QC Stability testing of biotechnological/biological products (CPMP/ICH/138/95)

ICH Topic Q5C, as outlined in document CPMP/ICH/138/95, addresses the stability testing of biotechnological and biological products. This guideline provides a framework for assessing the stability of these products over time, ensuring that they maintain their quality, safety, and efficacy throughout their shelf life. Below is an elaboration of ICH Q5C: 1. Purpose of ICH Q5C: The primary purpose of ICH Q5C is to establish principles and guidelines for conducting stability testing of biotechnological and biological products. The goal is to provide evidence that these products remain safe and effective during their intended shelf life. 2. Types of Products Covered: ICH Q5C applies to a wide range of biotechnological and biological products, including monoclonal antibodies, recombinant proteins, vaccines, gene therapies, and other biopharmaceuticals. 3. Stability Study Design: The guideline outlines the design of stability studies, including the selection of relevant storage conditions, ti...
Read more